Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC14 in Rapidly Progressive Amyotrophic Lateral Sclerosis
NCT03508453Phase 2Withdrawn
- Sponsor
- Implicit Bioscience
- Start
- Aug 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atibuclimab in amyotrophic lateral sclerosis (ALS), sponsored by Implicit Bioscience. Planned start Aug 2021; status: withdrawn.
02
Drugs
atibuclimab
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03508453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03508453.